Effect and Mechanism of Bifidobacterium animalis B94 in the Prevention and Treatment of Liver Injury in Rats

Zhang, Tianfang; Wang, Jie; Zhao, Yao; Ni, Lingmei; Zhao, Yifan; Wei, Shuang; Chen, Zuobing

doi:10.3389/fcimb.2022.914684

Cited by 5 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study reported the role of microbial therapy in reducing ALT levels in patients with nonalcoholic fatty liver disease (Loman et al, 2018). In addition, probiotic supplementation significantly reduced ALT levels and benefited liver injury in an animal model of acute liver injury and liver cirrhosis (Adawi et al, 2001;Liu et al, 2015;Liu et al, 2017;Zhang et al, 2022). In addition, treatment with probiotics prior to liver transplantation in cirrhotic patients was associated with improvements in early postoperative ALT (Grat et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis

Zhou

Liu

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundLiver cirrhosis is the end stage of various chronic liver diseases (CLDs). The gut microbiota can impact the liver environment and trigger chronic liver inflammation through the gut-liver axis. Alteration of the gut microbiota has become an effective strategy in the biological treatment of cirrhosis.MethodsTwenty-eight patients with liver cirrhosis and 16 healthy individuals were included, and fresh stool samples were collected. We analyzed changes in the gut microbiota between groups by 16S rRNA sequencing and evaluated the association between microbiota alterations and hepatic function. Additionally, 102 cirrhotic patients were retrospectively enrolled and divided into a probiotic group (n=44) and a nonprobiotic group (n=58) in addition to standard treatment for cirrhosis. Patients were monitored for hematological parameters and hepatic function during the six-month follow-up.ResultsThe gut microbiota profile of patients with cirrhosis was greatly different from that of healthy individuals, presenting with significantly reduced α diversity and decreased abundance of representative SCFA-producing bacteria including Firmicutes, Coprococcus and Clostridium IV. The pathogenic bacteria Gammaproteobacteria, Veillonella, and Bacilli were greatly enriched in cirrhotic patients. Additionally, patients with decompensated cirrhosis (DCPC) had a significantly reduced abundance of Oscillibacter compared to compensated cirrhosis (CPC), which is also a SCFA-producing bacteria, and the lower Firmicutes to Bacteroidetes ratio and enhanced MDR values were also shown in DCPC patients compared to CPC patients. In addition, the abundance of Firmicutes was negatively related to hepatic function in cirrhotic patients, including the levels of ALT, AST, and DBIL. From the retrospective study, we found that biochemical improvements in alanine transaminase (ALT) and total bilirubin (TBIL) were obtained in DCPC patients who received oral probiotic therapy compared with the nonprobiotic group.ConclusionSevere microbial dysbiosis existed in patients with liver cirrhosis, especially patients who reached the decompensatory stage. SCFA-producing bacteria were significantly reduced in cirrhosis. Altered gut microbiota cause changes in functional modules, which may contribute to cirrhosis progression and are associated with clinical prognosis. Adjuvant probiotic supplementation to enhance SCFA-producing bacteria can be a prospective therapy for patients with cirrhosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis

Zhou

Liu

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Lactobacillus and Bifidobacterium are typically beneficial bacterial genera. Bifidobacterium can exert nephroprotective effects through immunomodulation and also attenuate liver damage [ 35 , 36 ]. Cisplatin treatment induces the apoptosis of Lactobacillus , which may be the main reason for the significant decrease in the Lactobacillus level in the intestines of mice after cisplatin administration; restoration of intestinal Lactobacillus abundance is thought to be a favorable approach to repair cisplatin-induced oxidative stress and inflammatory damage in the liver and kidney [ 23 , 27 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Gut Microbiota Combined with Metabolomics Reveal the Mechanisms of Sika Deer Antler Protein on Cisplatin-Induced Hepatorenal Injury in Mice

Wang,

Li,

Wang

et al. 2023

Molecules

View full text Add to dashboard Cite

Cisplatin is a widely used antineoplastic drug, though its adverse effects, particularly its hepatorenal toxicity, limit its long-term application. Sika deer antler is a valuable traditional Chinese medicine (TCM) documented to possess the capacity for tonifying the kidney and regulating the liver, of which the sika deer antler protein is an important active ingredient. In this study, two protein fractions, SVPr1 and SVPr2, of sika deer antler were purified and administered to mice treated with cisplatin, and serum metabolome and fecal microbiota were measured using ultrahigh-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) and 16S rRNA gene sequencing. SVPr1 and SVPr2 significantly ameliorated cisplatin-induced liver and kidney injury and reduced mitochondrial dysfunction, oxidative stress, inflammatory response, and apoptosis. In addition, SVPr1 and SVPr2 impacted the gut microbiota structure of mice, significantly increasing the relative abundances of Lactobacillus, which deserves to be scrutinized. Moreover, SVPr1 and SVPr2 antagonism of cisplatin-induced hepatorenal injury may be related to the regulation of lysine degradation, tryptophan metabolism, and riboflavin metabolism pathways, significantly altering the levels of L-saccharopine, L-lysine, L-kynurenine, 3-methylindole, xanthurenic acid, riboflavin, and D-ribulose-5-phosphate. A correlation between the differential metabolites and Lactobacillus was identified. These findings increased the knowledge of the gut microbiota–metabolites axis mediated by SVPr1 and SVPr2, and may be able to contribute to the development of new therapeutic strategies for the simultaneous prevention and treatment of liver and kidney injury from cisplatin treatment.

show abstract

“…B94 with oral rehydration treatment significantly shortened the diarrheal period in acute rotavirus gastroenteritis infants/children (5 months to 5 years old), compared with control oral rehydration alone ( 40 ). In vivo study reported that B94 improved the gut microbiota and metabolic dysbiosis, thus reducing pathological abnormalities in gastrointestinal organs ( 43 ).…”

Section: Probiotic Research Against Infectious Disease In Pre-covid-1...mentioning

confidence: 99%

Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era

Kanauchi,

Low,

Jounai

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

The COVID-19 outbreak has caused significant global changes and increased public awareness of SARS-CoV-2. Substantial progress in developing vaccines, enhancing sanitation practices, and implementing various measures to combat the virus, including the utilization of probiotics has been made. This comprehensive review examined the medical impact of clinically proven probiotics on infectious diseases, considering three crucial time periods: before (pre-), during (mid-), and after (post-) COVID-19 pandemic era. This review also showed a perspective on the use of probiotics to stimulate the innate immune system and prevent infectious diseases. In pre-COVID-19 era, several probiotic strains were found to be clinically effective in addressing gastrointestinal infectious diseases, the common cold and flu. However, the mechanism by which probiotics exerted their antiviral effects remained relatively unclear during that period. Nevertheless, probiotics, Lactococcus lactis strain Plasma (LC-Plasma), and others have gained attention for their unique ability to modulate the immune system and demonstrate antiviral properties. While some probiotics have shown promise in alleviating gastrointestinal symptoms linked to COVID-19, their direct effectiveness in treating or preventing COVID-19 progression has not yet been conclusively established. As we transition into the post-COVID-19 era, the relationship between COVID-19 and plasmacytoid dendritic cells (pDCs), a vital component of the innate immune system, has been gradually elucidated. These findings are now being applied in developing novel vaccines and treatments involving interferons and in immune activation research using probiotics as adjuvants, comparable to CpG-DNA through TLR9. The role of the local innate immune system, including pDCs, as the first line of defense against viral infections has gained increasing interest. Moving forward, insight of the immune system and the crosstalk between probiotics and the innate immune system is expected to highlight the role of probiotics in adjunctive immunoregulatory therapy. In combination with drug treatments, probiotics may play a more substantial role in enhancing immune responses. The immunoregulatory approach using probiotics such as LC-Plasma, which can induce anti-infectious factors such as interferons, holds promise as a viable therapeutic and prophylactic option against viral infectious diseases due to their good safety profile and protective efficacy.

show abstract

Effect and Mechanism of Bifidobacterium animalis B94 in the Prevention and Treatment of Liver Injury in Rats

Cited by 5 publications

References 33 publications

Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis

Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis

Gut Microbiota Combined with Metabolomics Reveal the Mechanisms of Sika Deer Antler Protein on Cisplatin-Induced Hepatorenal Injury in Mice

Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era

Contact Info

Product

Resources

About